The absence of germline pathogenic variants in non-BRCA1/2 HRR genes in women aged ≥80, combined with the fact that only 50% of these variants were found in women with a GIS-positive tumour, suggest germline multi-gene panel testing has limited value in women aged ≥80 regardless of GIS status. The gene discussed is BRCA1; the disease is neoplasm.